| Primary |
| Bone Marrow Failure |
26.9% |
| Aplastic Anaemia |
22.8% |
| Premedication |
21.1% |
| Prophylaxis |
7.6% |
| Infection Prophylaxis |
3.5% |
| Cord Blood Transplant Therapy |
2.3% |
| Aplasia Bone Marrow |
1.8% |
| Heart Transplant |
1.8% |
| Acute Myeloid Leukaemia |
1.2% |
| Anaemia Haemolytic Autoimmune |
1.2% |
| Device Related Infection |
1.2% |
| Dyslipidaemia |
1.2% |
| Immunosuppressant Drug Therapy |
1.2% |
| Pancytopenia |
1.2% |
| Serum Sickness |
1.2% |
| Staphylococcal Infection |
1.2% |
| Transfusion |
1.2% |
| Antifungal Treatment |
0.6% |
| Antiviral Treatment |
0.6% |
| Aplasia |
0.6% |
|
| Urticaria |
13.0% |
| Serum Sickness |
7.4% |
| White Blood Cell Count Decreased |
7.4% |
| Disease Progression |
5.6% |
| Drug Ineffective |
5.6% |
| Pyrexia |
5.6% |
| Septic Shock |
5.6% |
| Treatment Failure |
5.6% |
| Adverse Drug Reaction |
3.7% |
| Aplastic Anaemia |
3.7% |
| Aspartate Aminotransferase Increased |
3.7% |
| Cytolytic Hepatitis |
3.7% |
| Death |
3.7% |
| Drug Intolerance |
3.7% |
| Hepatic Enzyme Increased |
3.7% |
| Hepatotoxicity |
3.7% |
| Muscular Weakness |
3.7% |
| Skin Test Positive |
3.7% |
| Spinal Deformity |
3.7% |
| Tonsillitis |
3.7% |
|
| Secondary |
| Prophylaxis Against Graft Versus Host Disease |
22.8% |
| Bone Marrow Conditioning Regimen |
15.8% |
| Stem Cell Transplant |
10.0% |
| Aplastic Anaemia |
9.0% |
| Prophylaxis |
8.0% |
| Antibiotic Prophylaxis |
6.1% |
| Antiviral Prophylaxis |
4.1% |
| Drug Use For Unknown Indication |
4.1% |
| Myelofibrosis |
2.9% |
| Bronchopulmonary Aspergillosis |
2.4% |
| Antifungal Prophylaxis |
2.2% |
| Aspergillosis |
1.9% |
| Bone Marrow Transplant |
1.9% |
| Acute Myeloid Leukaemia |
1.7% |
| Prophylaxis Against Transplant Rejection |
1.7% |
| Bone Marrow Failure |
1.5% |
| Aplasia Pure Red Cell |
1.0% |
| Chronic Lymphocytic Leukaemia |
1.0% |
| Heart Transplant |
1.0% |
| Immunosuppressant Drug Therapy |
1.0% |
|
| Hepatic Neoplasm Malignant Recurrent |
10.2% |
| Transplant Rejection |
10.2% |
| Graft Versus Host Disease |
8.5% |
| Immunosuppressant Drug Level Decreased |
6.8% |
| Viral Infection |
6.8% |
| Infection |
5.1% |
| Pyrexia |
5.1% |
| Respiratory Distress |
5.1% |
| Transplant Failure |
5.1% |
| Urticaria |
5.1% |
| Aneurysm |
3.4% |
| Chronic Graft Versus Host Disease |
3.4% |
| Cytomegalovirus Infection |
3.4% |
| Drug Interaction |
3.4% |
| Haemolysis |
3.4% |
| Hypersensitivity |
3.4% |
| Non-hodgkin's Lymphoma |
3.4% |
| Pneumocystis Jiroveci Pneumonia |
3.4% |
| Transaminases Increased |
3.4% |
| Decreased Appetite |
1.7% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
17.9% |
| Stem Cell Transplant |
9.4% |
| Bronchopulmonary Aspergillosis |
8.8% |
| Bone Marrow Transplant |
7.9% |
| Renal Transplant |
6.7% |
| Prophylaxis |
5.6% |
| Aplastic Anaemia |
5.3% |
| Product Used For Unknown Indication |
5.3% |
| Cord Blood Transplant Therapy |
4.7% |
| Drug Use For Unknown Indication |
4.7% |
| Bone Marrow Conditioning Regimen |
3.2% |
| Aplasia |
2.9% |
| Prophylaxis Against Transplant Rejection |
2.9% |
| Graft Versus Host Disease |
2.6% |
| Prophylaxis Against Renal Transplant Rejection |
2.3% |
| Respiratory Tract Infection |
2.3% |
| Surgical Preconditioning |
2.1% |
| Antibiotic Prophylaxis |
1.8% |
| Antiviral Prophylaxis |
1.8% |
| Chemotherapy |
1.8% |
|
| Transplant Rejection |
11.1% |
| Hepatic Fibrosis |
9.5% |
| Infection |
6.3% |
| Renal Failure Acute |
6.3% |
| Transfusion-related Acute Lung Injury |
6.3% |
| Osteonecrosis |
4.8% |
| Renal Impairment |
4.8% |
| Sepsis |
4.8% |
| Toxic Encephalopathy |
4.8% |
| Ureteric Obstruction |
4.8% |
| Vasculitis |
4.8% |
| Viith Nerve Paralysis |
4.8% |
| Vomiting |
4.8% |
| Aplastic Anaemia |
3.2% |
| Bacterial Sepsis |
3.2% |
| Drug Ineffective |
3.2% |
| Drug Interaction |
3.2% |
| Epstein-barr Virus Infection |
3.2% |
| Graft Versus Host Disease |
3.2% |
| Mucous Stools |
3.2% |
|
